Neurocrine Biosciences Inc (NBIX)

Return on assets (ROA)

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Net income (ttm)	US$ in thousands	249,700	191,000	176,400	64,000	154,500	58,200	12,200	71,400	89,600	444,800	364,700	402,000	407,300	93,400	204,800	176,500	37,000	21,078	18,042	-39,171
Total assets	US$ in thousands	3,251,400	2,848,200	2,613,100	2,359,800	2,368,700	2,143,400	2,005,700	2,144,500	2,072,500	2,017,300	1,956,400	1,846,400	1,734,700	1,502,600	1,515,600	1,361,900	1,306,000	1,179,940	1,066,860	957,723
ROA		7.68%	6.71%	6.75%	2.71%	6.52%	2.72%	0.61%	3.33%	4.32%	22.05%	18.64%	21.77%	23.48%	6.22%	13.51%	12.96%	2.83%	1.79%	1.69%	-4.09%

December 31, 2023 calculation

ROA = Net income (ttm) ÷ Total assets
= $249,700K ÷ $3,251,400K
= 7.68%

Neurocrine Biosciences, Inc.'s return on assets (ROA) has shown variability in recent quarters. The ROA for Q4 2023 was 7.68%, representing an improvement compared to the previous quarter at 6.71%. This indicates that the company generated 7.68 cents of profit for every dollar of assets in the most recent quarter. Looking at the trend over the past eight quarters, there have been fluctuations in ROA, with peaks and troughs observed. The company's performance in Q1 2023 and Q3 2022 stood out with ROAs of 2.71% and 2.72%, respectively, indicating lower profitability relative to other quarters. Conversely, Q4 2022 and Q2 2022 marked higher ROAs at 6.52% and 6.75%, respectively, reflecting stronger asset utilization and profitability levels during those periods. Overall, Neurocrine Biosciences, Inc. has demonstrated varying levels of efficiency in generating profits from its assets, highlighting the importance of continuous monitoring and management of asset utilization strategies to enhance overall business performance.